351 related articles for article (PubMed ID: 16566834)
1. Cerebrospinal fluid HIV-1 RNA, intrathecal immunoactivation, and drug concentrations after treatment with a combination of saquinavir, nelfinavir, and two nucleoside analogues: the M61022 study.
Yilmaz A; Fuchs D; Hagberg L; Nillroth U; Ståhle L; Svensson JO; Gisslén M
BMC Infect Dis; 2006 Mar; 6():63. PubMed ID: 16566834
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen.
Yilmaz A; Ståhle L; Hagberg L; Svennerholm B; Fuchs D; Gisslén M
Scand J Infect Dis; 2004; 36(11-12):823-8. PubMed ID: 15764168
[TBL] [Abstract][Full Text] [Related]
3. Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.
Reiser M; Salzberger B; Stiepel A; Hoetelmans R; Diehl V; Fätkenheuer G
Eur J Med Res; 1999 Feb; 4(2):54-8. PubMed ID: 10066640
[TBL] [Abstract][Full Text] [Related]
4. Continuing intrathecal immunoactivation despite two years of effective antiretroviral therapy against HIV-1 infection.
Abdulle S; Hagberg L; Svennerholm B; Fuchs D; Gisslén M
AIDS; 2002 Nov; 16(16):2145-9. PubMed ID: 12409735
[TBL] [Abstract][Full Text] [Related]
5. A randomized trial of nelfinavir, ritonavir, or delavirdine in combination with saquinavir-SGC and stavudine in treatment-experienced HIV-1-infected patients.
Smith D; Hales G; Roth N; Law M; Ray J; Druett J; Mitchell J; Mills G; Doong N; Franklin R;
HIV Clin Trials; 2001; 2(2):97-107. PubMed ID: 11590517
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine.
Gisolf EH; Enting RH; Jurriaans S; de Wolf F; van der Ende ME; Hoetelmans RM; Portegies P; Danner SA
AIDS; 2000 Jul; 14(11):1583-9. PubMed ID: 10983645
[TBL] [Abstract][Full Text] [Related]
7. Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy.
Yilmaz A; Verhofstede C; D'Avolio A; Watson V; Hagberg L; Fuchs D; Svennerholm B; Gisslén M
J Acquir Immune Defic Syndr; 2010 Dec; 55(5):590-6. PubMed ID: 20847699
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir.
Kravcik S; Gallicano K; Roth V; Cassol S; Hawley-Foss N; Badley A; Cameron DW
J Acquir Immune Defic Syndr; 1999 Aug; 21(5):371-5. PubMed ID: 10458617
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of nelfinavir in patients switched from ritonavir/saquinavir combination antiretroviral therapy.
Hellinger JA; Cohen CJ; Stein AJ; Gallant JE; Gathe J; Keiser P
HIV Clin Trials; 2000; 1(2):25-8. PubMed ID: 11590495
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection.
Gisslén M; Fuchs D; Svennerholm B; Hagberg L
J Acquir Immune Defic Syndr; 1999 Aug; 21(4):271-6. PubMed ID: 10428104
[TBL] [Abstract][Full Text] [Related]
11. Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations.
Lafeuillade A; Solas C; Halfon P; Chadapaud S; Hittinger G; Lacarelle B
HIV Clin Trials; 2002; 3(1):27-35. PubMed ID: 11819183
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of nelfinavir-based treatment in the central nervous system of HIV-1 infected patients.
Karlström O; Ståhle L; Perrin L; Tegude H; Sönnerborg A
Scand J Infect Dis; 2006; 38(5):371-4. PubMed ID: 16709540
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors.
Kirk O; Lundgren JD; Pedersen C; Mathiesen LR; Nielsen H; Katzenstein TL; Obel N; Gerstoft J
Antivir Ther; 2003 Dec; 8(6):595-602. PubMed ID: 14760893
[TBL] [Abstract][Full Text] [Related]
14. Nelfinavir. A review of its therapeutic efficacy in HIV infection.
Jarvis B; Faulds D
Drugs; 1998 Jul; 56(1):147-67. PubMed ID: 9664204
[TBL] [Abstract][Full Text] [Related]
15. Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy.
Edén A; Price RW; Spudich S; Fuchs D; Hagberg L; Gisslén M
J Infect Dis; 2007 Dec; 196(12):1779-83. PubMed ID: 18190258
[TBL] [Abstract][Full Text] [Related]
16. Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1--infected patients with and without AIDS dementia complex.
Aweeka F; Jayewardene A; Staprans S; Bellibas SE; Kearney B; Lizak P; Novakovic-Agopian T; Price RW
J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Jan; 20(1):39-43. PubMed ID: 9928728
[TBL] [Abstract][Full Text] [Related]
17. Saquinavir soft-gel capsule: an updated review of its use in the management of HIV infection.
Figgitt DP; Plosker GL
Drugs; 2000 Aug; 60(2):481-516. PubMed ID: 10983742
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy and safety of twice-daily saquinavir soft gelatin capsules (SGC), with or without nelfinavir, and three times daily saquinavir-SGC, in triple combination therapy for HIV infection: 100-week follow-up.
Greenberg RN; Feinberg J; Goodrich J; Pilson RS; Siemon-Hryczyk P
Antivir Ther; 2003 Feb; 8(1):37-42. PubMed ID: 12713062
[TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal fluid viral load, virus isolation, and intrathecal immunoactivation in HIV type 2 infection.
Arvidson N; Gisslén M; Albert J; Brandin E; Svennerholm B; Fuchs D; Hagberg L
AIDS Res Hum Retroviruses; 2004 Jul; 20(7):711-5. PubMed ID: 15307916
[TBL] [Abstract][Full Text] [Related]
20. Plasma drug levels, genotypic resistance, and virological response to a nelfinavir plus saquinavir-containing regimen.
Casado JL; Moreno S; Hertogs K; Dronda F; Antela A; Dehertogh P; Perez-Elías MJ; Moreno A;
AIDS; 2002 Jan; 16(1):47-52. PubMed ID: 11741162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
